DaVita Inc. stock gains on strong Q2 2026 results and upbeat guidance

Published on 09/19/2026 at 20:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita Inc. stock is trading near USD 183 after Q2 2026 earnings per share of USD 4.02 beat estimates and revenue grew 5.2 percent year over year. The company’s fiscal 2026 EPS guidance of USD 14.10 to 15.20 underpins the current valuation as of September 19, 2026.

Modernes Dialysezentrum mit Pflegepersonal und Patienten in heller Klinikumgebung — DaVita Inc. Dialysezentrum mit modernen Behandlungsstühlen und medizinischem Pflegepersonal in Denver, ISIN US23918K1088, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23918K1088) is trading around USD 183 on the New York Stock Exchange after the kidney care provider delivered stronger Q2 2026 results, with earnings per share of USD 4.02 and revenue up 5.2 percent year over year to USD 3.55 billion as of the latest data on September 19, 2026.

Q2 2026 earnings beat and guidance support valuation

According to MarketBeat on September 19, 2026, DaVita reported Q2 2026 earnings per share of USD 4.02, beating analyst estimates of USD 3.88 by USD 0.14.

In the same quarter, revenue rose 5.2 percent year over year to USD 3.55 billion, illustrating mid-single-digit top-line growth in DaVita’s kidney care operations in Q2 2026 compared with the prior-year period, as highlighted by MarketBeat.

Looking ahead, DaVita has issued fiscal 2026 EPS guidance in a range of USD 14.10 to USD 15.20, which, based on current estimates, implies earnings growth and provides a numerical anchor for investors assessing the stock’s valuation in 2026, according to MarketBeat.

Analyst consensus and shareholder activity

Analyst sentiment toward DaVita Inc. stock remains broadly constructive. As summarized by MarketBeat on September 19, 2026, the stock carries a Moderate Buy consensus rating based on four Buy recommendations and three Hold ratings from sell-side firms.

The same overview indicates that the average analyst price target for DaVita stands at USD 233.43, compared with a recent share price of USD 183.59, suggesting implied upside of around USD 49.84 per share relative to the current level as of mid-September 2026, according to MarketBeat.

The MarketBeat report also notes institutional portfolio adjustments. Corient Private Wealth LP reduced its DaVita holdings by 49 percent in the second quarter of 2026, selling 26,571 shares and retaining 27,685 shares valued at approximately USD 6.16 million, according to MarketBeat.

Valuation, market metrics and investor takeaway

DaVita Inc. stock opened at USD 183.59 in the latest session referenced by MarketBeat on September 19, 2026, corresponding to a market capitalization of USD 11.71 billion.

At this price level, DaVita trades on a price-earnings ratio of 15.02 and a price-to-earnings-growth ratio of 0.47, figures that indicate a valuation profile combining mid-teens earnings multiple with a PEG ratio below 1, as reported by MarketBeat.

For investors, the key numerical comparison currently lies between DaVita’s fiscal 2026 EPS guidance range of USD 14.10 to USD 15.20 and sell-side expectations of around USD 14.57 per share for the year, a balance that frames the earnings outlook and helps contextualize the USD 233.43 average price target versus the USD 183.59 share price as of September 19, 2026, based on data cited by MarketBeat.

DaVita stock price and trading snapshot

As of the most recent trading data around September 19, 2026, DaVita Inc. stock is quoted near USD 183.86 on the New York Stock Exchange in United States dollars, with price indications around that level also reflected in market snapshots that show the shares modestly higher on the day and supported by an equity value in the low-double-digit billion range in USD.